First International Conference on Harmonisation. Brussels, November 1991. Proceedings D'Arcy PF and Harron DWG, Eds), Belfast: The Queen's University of Belfast Press, 1992.
2.
Conference on the Integration of Pharmacokinetics, Pharmacodynamics and Toxicokinetics in Rational Drug Development, sponsored by the American Association of Pharmaceutical Scientists, US Food and Drug Administration and the American Society for Clinical Pharmacology and Therapeutics , held at Arlington, VA, April 24-26, 1991. Report published by Peck CC, Barr WH, Benet LZ, et al. Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development. Clinical Pharmacology and Therapeutics 1992; 51: 465-73.
3.
Drug Information Association.Symposium on "Recent Considerations on the Design, Interpretation and Evaluation of Rodent Carcinogenicity Studies," held at Rockville, MD, U.S.A., September 30 and October 1, 1991 .
4.
Blakiston's Gould Medical Dictionary, 4th Edition, New York: McGraw-Hill , 1979.
5.
Environmental Protection Agency, USA.Proposed guidelines for exposure-related measurements. Federal Register1988; 53: 48830-53.
6.
Weinstein IBNon-mutagenic mechanisms in carcinogenesis: role of protein kinase C in signal transduction and growth control. Environmental Health Perspectives1991; 93: 175-9.
7.
Oohashi Y., Ishioka T., Wakabaya K. & Kuwabara N.A study on carcinogenesis induced by degraded carrageenan arising from squamous metaplasia of the rat colorectum. Cancer Letters1981; 14: 262-72.
8.
Wald NJ & Doll R (Eds). Interpretation of negative epidemiological evidence for carcinogenicity. International Agency for Research on Cancer Research, Lyon: Scientific Publication1985; No. 65, 101-21.
